Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Jonathan Hamill, Jaime E. C. Hallak, Serdar Dursun, Glen B. Baker
Current Neuropharmacology March 2, 2018 DOI: 10.2174/1570159x16666180125095902 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
Background: Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use it routinely to foster a spiritual experience. More recently, it is being used in Europe and North America, not only for religious or healing reasons, but also for recreation.
Objective: To review ayahuasca’s behavioral effects, possible adverse effects, proposed mechanisms of action and potential clinical uses in mental illness.
Method: We searched Medline, in English, using the terms ayahuasca, dimethyltryptamine, Banisteriopsis caapi, and Psychotria viridis and reviewed the relevant publications.
Results: The following aspects of ayahuasca are summarized: Political and legal factors; acute and chronic psychological effects; electrophysiological studies and imaging; physiological effects; safety and adverse effects; pharmacology; potential psychiatric uses.
Conclusion: Many years of shamanic wisdom have indicated potential therapeutic uses for ayahuasca, and several present day studies suggest that it may be useful for treating various psychiatric disorders and addictions. The side effect profile appears to be relatively mild, but more detailed studies need to be done. Several prominent researchers believe that government regulations with regard to ayahuasca should be relaxed so that it could be provided more readily to recognized, credible researchers to conduct comprehensive clinical trials.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Reviews ayahuasca's pharmacology and effects and concludes that several studies suggest it may be useful for treating psychiatric disorders and addictions with a relatively mild side-effect profile.
Synthesized
Comparable studies
Other narrative reviews on ayahuasca for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment | 2012 | Review | |
| The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges | 2021 | Review | |
| Can psychedelic compounds play a part in drug dependence therapy? Patients with substance dependency | 2015 | Review | |
| Advances in Psychedelic Medicine | 2019 | Review | |
| Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders Individuals with mental and substance use disorders | 2023 | Scoping review |
Citations in the library
Cited by 139
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review Journal of Psychopharmacology August 26, 2022
- Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology February 1, 2021
- The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial Frontiers in Pharmacology November 19, 2019
- Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers Scientific Reports November 18, 2021
and 134 more in the library
Cites 110
- Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor Molecular Pharmacology December 1, 2001
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator Science February 13, 2009
- Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Brazilian Journal of Psychiatry March 1, 2015
- Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Journal of Clinical Psychopharmacology December 11, 2015
- The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network PLoS One February 18, 2015
and 105 more in the library